Pharma's R&D shift to orphan drugs threatens health care budgets

03/10/2014 | Toronto Star, The

The pharmaceutical industry's increasing focus on research to develop drugs for rare genetic conditions could break health care budgets around the world, according to this article. The search for treatments for rare ailments will bring real benefits to patients, said Jared Rhines of Rx&D, a group representing research-based drugmakers in Canada. The trouble with niche drugs is that they can be very high-priced, said Dr. Michael Rieder of the Canadian Pediatric Society.

View Full Article in:

Toronto Star, The

Published in Brief: